Compare FNWB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | ASMB |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 512.1M |
| IPO Year | 2012 | 2010 |
| Metric | FNWB | ASMB |
|---|---|---|
| Price | $10.25 | $25.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $13.50 | ★ $44.20 |
| AVG Volume (30 Days) | 18.0K | ★ 296.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | 36.00 | ★ 91.78 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | $638.39 |
| P/E Ratio | $261.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.25 | $20.23 |
| 52 Week High | $12.52 | $39.71 |
| Indicator | FNWB | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 39.48 |
| Support Level | $9.55 | $25.86 |
| Resistance Level | $10.38 | $30.62 |
| Average True Range (ATR) | 0.26 | 1.71 |
| MACD | -0.08 | -0.95 |
| Stochastic Oscillator | 11.02 | 2.07 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.